|
|
|
|
Active in vitro but toxic in cats
|
|
|
|
Active in vitro but toxic in cats
|
|
Human interferon-α, SC, high dose
|
Although effective in vitro against FCoV, SC treatment did not work in an experimental trial
|
|
Human interferon-α, PO, low dose
|
No trials. Only acts as immunostimulant if given orally; immune stimulation should be avoided in cats with FIP
|
|
|
|
Single placebo-controlled study of naturally occurring cases and one uncontrolled study
|
No benefit was observed (level 1 study); may require further studies in view of anecdotal clinical evidence (4)
|
Polyprenyl immunostimulant (investigational drug)
|
Upregulation biosynthesis of mRNA of TH1 cytokines, uncontrolled study treating three noneffusive cases, long survival
|
May have some beneficial effect in noneffusive FIP (3); controlled studies required
|
|
|
Prednisolone/dexamethasone (immunosuppressive doses)
|
No controlled studies; some cats improved during treatment and survived for several months; does not cure FIP
|
Currently supportive treatment of choice (3); if effusion is present, dexamethasone intrathoracic or intraperitoneal may be helpful
|
|
|
Aimed at treating vasculitis
|
Ineffective in one case study (4)
|
|
|
Thromboxane synthesis inhibitor aimed at treating inflammatory response; only used in two cases with beneficial effect
|
Controlled studies needed (3)
|
|
|
Immunosuppressive; no published studies
|
Not recommended; more directed against cellular immunity than humoral (lack of data) (4)
|
|
|
Immunosuppressive; no published studies
|
Might be considered in combination with glucocorticoids (4)
|
|
|
Immunosuppressive; no published studies
|
Might be considered in combination with glucocorticoids (4)
|
|
|
Toxic in cats; immunosuppressive; no published studies
|
|
Acetylsalicylic acid (aspirin), platelet inhibitory dosage
|
To treat inflammatory response as well as vasculitis; no published studies
|
May have some beneficial effect, but adverse effects possible if used in combination with high-dose glucocorticoids
|
